| Status: Recommended with restrictions | |||
Olanzapine (ZypAdhera®) is recommended as an option for restricted use within NHS Wales. Olanzapine (ZypAdhera®) is licensed for the maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine. Olanzapine (ZypAdhera®) is restricted for use in a subpopulation of patients more appropriately managed with a long acting injection formulation because of difficulties adhering to an oral olanzapine regimen, indicated by recurrent relapse or exacerbation of symptoms. Olanzapine (ZypAdhera®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | olanzapine (ZypAdhera®) | ||
| Formulation | 210 mg, 300 mg, 405 mg powder and solvent for prolonged-release suspension for injection | ||
| Reference number | 2991 | ||
| Indication | Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine |
||
| Company | Eli Lilly & Co Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Resubmission | ||
| Status | Recommended with restrictions | ||
| Advice number | 1516 | ||
| NMG meeting date | 11/05/2016 | ||
| AWMSG meeting date | 15/06/2016 | ||
| Ratification by Welsh Government | 26/07/2016 | ||
| Date of issue | 27/07/2016 | ||
| Date of last review | 01/08/2019 | ||